Navigation Links
Pharmos Corporation Announces Board and Management Changes
Date:1/3/2008

yte), ExSAR and Targent.

Mr. Johnston served as CEO of Cytogen from July 1988 to April 1989. He is also a member of the Advisory Council of the Department of Molecular Biology at Princeton University and the Executive Committee of the Friends of the Institute for Advanced Study in Princeton, as well as Founder and President of Educational Ventures, a foundation focused on funding improvements in the educational system; and Vice-Chairman of Center for Education Reform (CER) an advocate for charter schools. Mr. Johnston received his B.A. from Princeton University and his M.B.A. from New York University.

S. Colin Neill

S. Colin Neill who becomes President of the Company, became Senior Vice President, Chief Financial Officer, Secretary and Treasurer of Pharmos in October 2006. From September 2003 to October 2006, Mr. Neill served as Chief Financial Officer, Treasurer and Secretary of Axonyx, Inc. a biopharmaceutical company that developed products and technologies to treat Alzheimer's disease and other central nervous system disorders, where he played an integral role in the merger between Axonyx and TorreyPines Therapeutics Inc., a privately- held biopharmaceutical company. From 1998 to 2001, Mr. Neill served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer of ClinTrials Research Inc., a $100 million publicly traded global contract research organization in the drug development business. Mr. Neill played a key role in the successful sale of the company in 2001. Mr. Neill graduated from Trinity College, Dublin with a first class honors degree in Business / Economics and he holds a masters degree in Accounting and Finance from the London School of Economics. He is a Certified Public Accountant in New York State and a Chartered Accountant in Ireland.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervo
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
2. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
3. Pharmos Corporation Reports 2007 Third Quarter Results
4. Pharmos Issues Letter to Shareholders
5. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
6. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
7. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Designation Process and Saves Lives, HARRISBURG, Pa., Aug. ... Web portal that will enable individuals to,sign up as ... driver,s,license or photo ID card is up for renewal ... Web portal, http://www.donatelife-pa.org, will link visitors to ...
... - Despite outcome, CEO Mark McDade to resign ... 20 PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ... the company,s chief executive officer (CEO), Mark McDade,found ... breach of,fiduciary duty by McDade to corroborate the ...
... Fisher,Scientific Inc. (NYSE: TMO ) announced today ... and chief executive,officer, are adopting stock- trading programs ... the future sale of company stock. Mr.,Dekkers, who ... August,15-17, 2007, has adopted a plan for the ...
Cached Biology Technology:Web Portal Makes Organ Donation Easy 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... April 2009 A major effort from within ... of an exceptional supplement by the Elsevier journal ... ). The supplement provides extensive studies based on ... niger and Aspergillus nidulans. The publication was enabled ...
... suffer medical complications from hypodermic needles that penetrate too ... MIT engineers and colleagues aims to prevent this from ... which is purely mechanical, is based on concepts borrowed ... needle containing a filament that acts as a guide ...
... down the constituent of olive oil that gives greatest protection ... major antioxidants in olive oil, Portuguese researchers showed that one, ... other part of olive oil. "These findings provide the ... seen in people who have olive oil in their diet," ...
Cached Biology News:MIT: Novel needle could cut medical complications 2
... RNasin Ribonuclease Inhibitors have broad spectrum RNase ... RNases of the neutral type (1). The ... noncovalently binding to RNases in a 1:1 ... of RNasin Ribonuclease Inhibitor to RNase (e.g., ...
... nucleic acids ,The GC-RICH PCR System, ... a proofreading polymerase, powers through templates that ... other polymerases and other blends of polymerases. ... the unique GC-RICH Resolution Solution combine to ...
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
B-FABP (FL-132)...
Biology Products: